147 related articles for article (PubMed ID: 11350909)
21. Protective effect of saponins from Panax notoginseng against doxorubicin-induced cardiotoxicity in mice.
Liu L; Shi R; Shi Q; Cheng Y; Huo Y
Planta Med; 2008 Feb; 74(3):203-9. PubMed ID: 18260050
[TBL] [Abstract][Full Text] [Related]
22. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
Narla RK; Chen CL; Dong Y; Uckun FM
Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
[TBL] [Abstract][Full Text] [Related]
23. Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase.
Kaiserová H; Simůnek T; van der Vijgh WJ; Bast A; Kvasnicková E
Biochim Biophys Acta; 2007 Sep; 1772(9):1065-74. PubMed ID: 17572073
[TBL] [Abstract][Full Text] [Related]
24. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of monohydroxyethylrutoside in healthy volunteers.
Willems AM; Bruynzeel AM; Kedde MA; van Groeningen CJ; Bast A; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 May; 57(5):678-84. PubMed ID: 16136309
[TBL] [Abstract][Full Text] [Related]
26. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
27. A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro.
Abou-El-Hassan MA; Rabelink MJ; van der Vijgh WJ; Bast A; Hoeben RC
Br J Cancer; 2003 Dec; 89(11):2140-6. PubMed ID: 14647150
[TBL] [Abstract][Full Text] [Related]
28. New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity.
van Acker FA; Hulshof JW; Haenen GR; Menge WM; van der Vijgh WJ; Bast A
Free Radic Biol Med; 2001 Jul; 31(1):31-7. PubMed ID: 11425487
[TBL] [Abstract][Full Text] [Related]
29. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.
Feleszko W; Mlynarczuk I; Balkowiec-Iskra EZ; Czajka A; Switaj T; Stoklosa T; Giermasz A; Jakóbisiak M
Clin Cancer Res; 2000 May; 6(5):2044-52. PubMed ID: 10815931
[TBL] [Abstract][Full Text] [Related]
30. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
32. Angelica sinensis: a novel adjunct to prevent doxorubicin-induced chronic cardiotoxicity.
Xin YF; Zhou GL; Shen M; Chen YX; Liu SP; Chen GC; Chen H; You ZQ; Xuan YX
Basic Clin Pharmacol Toxicol; 2007 Dec; 101(6):421-6. PubMed ID: 17971065
[TBL] [Abstract][Full Text] [Related]
33. Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts.
Jones LW; Eves ND; Courneya KS; Chiu BK; Baracos VE; Hanson J; Johnson L; Mackey JR
Clin Cancer Res; 2005 Sep; 11(18):6695-8. PubMed ID: 16166449
[TBL] [Abstract][Full Text] [Related]
34. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Han GZ; Liu ZJ; Shimoi K; Zhu BT
Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
[TBL] [Abstract][Full Text] [Related]
35. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
Zhang Y; Song S; Yang F; Au JL; Wientjes MG
J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
[TBL] [Abstract][Full Text] [Related]
36. Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice.
van Acker SA; Voest EE; Beems DB; Madhuizen HT; de Jong J; Bast A; van der Vijgh WJ
Cancer Res; 1993 Oct; 53(19):4603-7. PubMed ID: 8402634
[TBL] [Abstract][Full Text] [Related]
37. Sustained protective effects of 7-monohydroxyethylrutoside in an in vivo model of cardiac ischemia-reperfusion.
De Celle T; Heeringa P; Strzelecka AE; Bast A; Smits JF; Janssen BJ
Eur J Pharmacol; 2004 Jun; 494(2-3):205-12. PubMed ID: 15212976
[TBL] [Abstract][Full Text] [Related]
38. The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models.
Uchegbu IF; Double JA; Kelland LR; Turton JA; Florence AT
J Drug Target; 1996; 3(5):399-409. PubMed ID: 8866659
[TBL] [Abstract][Full Text] [Related]
39. Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo.
Zhang Y; Berger SA
Cancer Chemother Pharmacol; 2003 May; 51(5):407-14. PubMed ID: 12687290
[TBL] [Abstract][Full Text] [Related]
40. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
De Cesare M; Pratesi G; Perego P; Carenini N; Tinelli S; Merlini L; Penco S; Pisano C; Bucci F; Vesci L; Pace S; Capocasa F; Carminati P; Zunino F
Cancer Res; 2001 Oct; 61(19):7189-95. PubMed ID: 11585754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
